Viewing Study NCT01492361

Bugs

Ignite Creation Date: 2025-12-24 @ 12:07 PM

Ignite Modification Date: 2026-02-07 @ 10:06 PM

Study NCT ID: NCT01492361

Status: COMPLETED

Last Update Posted: 2022-04-14

First Post: 2011-12-13

Is Gene Therapy: True

Has Adverse Events: True

Brief Title: A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

Sponsor: Amarin Pharma Inc.

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions:

Condition Brief	Condition Text	View

None	Cardiovascular Diseases	View

Keywords:

Keyword Brief	Keyword Text	View

None	Coronary Artery Disease	View
None	Myocardial Ischemia	View
None	Coronary Disease	View
None	Heart Diseases	View
None	Acute Coronary Syndrome	View
None	Cardiovascular Diseases	View
None	Arteriosclerosis	View
None	Arterial Occlusive Diseases	View
None	Vascular Diseases	View
None	Angina Pectoris	View
None	Chest Pain	View
None	Anticholesteremic Agents	View
None	Hypolipidemic Agents	View
None	Lipid Regulating Agents	View
None	Hypertriglyceridemia	View
None	Omega-3 Fatty Acids	View
None	Statin	View
None	Triglycerides	View
None	EPA	View
None	Docosahexaenoic Acid	View
None	Fish	View
None	Fatty acids	View
None	Fibrates	View
None	Niacin	View
None	Lipids	View
None	Lipoprotein	View
None	Atorvastatin	View
None	Lovaza	View
None	Simvastatin	View
None	Lovastatin	View
None	Pravastatin	View
None	Fluvastatin	View
None	Rosuvastatin	View
None	Trilipix	View
None	Vytorin	View
None	Simcor	View
None	Ezetimibe	View
None	Zetia	View
None	Ethyl-EPA	View
None	Ethyl Icosapentate	View
None	Crestor	View
None	Zocor	View
None	Lipitor	View
None	LDL	View
None	HDL	View
None	Cholesterol	View
None	Dyslipidemia	View
None	AMR101	View
None	Cardiovascular Disease, Unspecified	View
None	VASCEPA	View
None	Icosapent Ethyl	View